Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hehir

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Neurology. Education|October 3, 2024
The Neuromuscular Portal and Match: Working Toward a More Fair, Equitable, and Transparent ProcessRuple S Laughlin, Shirlyn Adkins, Michael Baer, et al.
Annals of Clinical and Translational Neurology|August 3, 2024
Protein-extending ACTN2 frameshift variants cause variable myopathy phenotypes by protein aggregationJohanna Ranta-Aho, Kevin J Felice, Per Harald Jonson, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Rare <i>ACTN2</i> Frameshift Variants Resulting in Protein Extension Cause Distal Myopathy and Hypertrophic Cardiomyopathy through Protein AggregationJohanna Ranta-Aho, Kevin J Felice, Per Harald Jonson, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Neurology. Education|October 3, 2024
The Neuromuscular Portal and Match: Working Toward a More Fair, Equitable, and Transparent ProcessRuple S Laughlin, Shirlyn Adkins, Michael Baer, et al.
Annals of Clinical and Translational Neurology|August 3, 2024
Protein-extending ACTN2 frameshift variants cause variable myopathy phenotypes by protein aggregationJohanna Ranta-Aho, Kevin J Felice, Per Harald Jonson, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Rare <i>ACTN2</i> Frameshift Variants Resulting in Protein Extension Cause Distal Myopathy and Hypertrophic Cardiomyopathy through Protein AggregationJohanna Ranta-Aho, Kevin J Felice, Per Harald Jonson, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Neurology|May 6, 2018
Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRIKelly G Gwathmey, Reza Sadjadi, William B Horton, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 5